胰臟癌診斷市場規模、佔有率和成長分析：按產品類型、技術、應用、癌症類型、最終用戶、檢體類型和地區分類－2026-2033年產業預測

2024 年全球胰臟癌診斷市場價值為 34 億美元，預計到 2025 年將成長至 36.9 億美元，到 2033 年將成長至 70.9 億美元，預測期（2026-2033 年）複合年成長率為 8.5%。

胰臟癌診斷市場的主要驅動力是迫切需要改進的檢測方法，這刺激了大量的投資和創新。包括影像技術、血清和組織生物標記以及資訊學在內的多種診斷方法正在協同作用，以提高診斷、分期和治療策略的準確性。由於胰臟癌通常發現較晚且存活率較低，因此有效的診斷對患者的預後和醫療資源的分配至關重要。目前的重點正從CA19-9和CT成像等傳統方法轉向超音波、基因組學和液態生物檢體等更先進的方法。此外，技術進步，特別是人工智慧成像和高靈敏度檢測的進步，正在推動市場成長，而價格合理的就地檢驗有望擴大檢測範圍並促進持續的研究舉措。

全球胰臟癌診斷市場按產品類型、技術、應用、癌症類型、最終用戶、檢體類型和地區進行細分。依產品類型分類，市場分為影像檢查、生物標記檢測、分子診斷檢測、切片檢查設備和試劑/耗材。按技術分類，市場分為基於PCR的診斷、次世代定序（NGS）、免疫檢測、影像技術和液態生物檢體。依應用分類，市場分為早期檢測、腫瘤分期、治療監測和復發監測。依癌症類型分類，市場分為外分泌性胰臟癌和胰臟神經內分泌腫瘤（PNET）。依最終用戶分類，市場分為醫院、診斷檢查室、癌症研究中心和專科診所。依檢體類型分類，市場分為血液、組織切片檢查和胰液。依地區分類，市場分為北美、歐洲、亞太、拉丁美洲以及中東和非洲。

全球胰臟癌診斷市場成長要素

全球胰臟癌診斷市場正受到製藥和生技公司加強對分子診斷投資的顯著推動。資金籌措的激增增強了研究能力，並推動了旨在提高胰臟癌檢測準確性的創新檢測方法和平台的開發。資源的增加使企業能夠透過發現新的生物標記、進行必要的檢驗研究以及與學術機構和產業夥伴合作，加速研究成果的商業化。這種持續的投資將透過加強必要的基礎設施、培養專業人才以及簡化先進診斷測試的部署，擴大臨床實踐中胰腺癌檢測尖端解決方案的普及範圍。

全球胰臟癌診斷市場面臨的限制因素

全球胰臟癌診斷市場面臨許多挑戰，包括基層醫療機構普遍缺乏相關知識以及低效率的轉診模式導致專科會診延誤。這種情況阻礙了對疑似胰臟癌患者的早期篩檢和及時診斷，從而降低了對先進診斷工具的需求。在許多情況下，患者就診時症狀特異性，導致確診時已處於較晚期，這削弱了早期檢測價值的認可。此外，臨床惰性和保守的轉診做法進一步限制了創新診斷方法的應用，導致患者繼續依賴傳統治療途徑，阻礙了市場整體成長。

全球胰臟癌診斷市場趨勢

全球胰臟癌診斷市場正呈現出人工智慧 (AI) 技術融合的顯著趨勢。這項轉變利用 AI 分析影像和病理數據，提高了診斷的準確性和速度，使醫療專業人員能夠更有效率地識別需要特殊照護的患者。 AI 解決方案供應商與醫療機構之間的合作正在推動檢驗演算法和效用研究的開發，這對於改善診斷流程至關重要。此外，AI 與電子健康記錄和協作平台的無縫整合正在簡化患者的治療路徑，最終提高胰臟癌治療中標準護理的品質和臨床決策支援水準。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢
• 價值鏈分析
• 案例研究
• 技術評估
• 客戶和採購標準分析
• 管道分析
• 疾病流行病學

全球胰臟癌診斷市場規模：依產品類型分類

• 影像檢查
• 生物標記檢測
• 分子診斷測試
• 切片檢查裝置
• 試劑和耗材

全球胰臟癌診斷市場規模：依技術分類

• 基於PCR的診斷
• 次世代定序（NGS）
• 免疫檢測
• 成像技術
• 液態生物檢體

全球胰臟癌診斷市場規模：按應用分類

• 早期檢測
• 腫瘤分期
• 治療監測
• 復發監測

全球胰臟癌診斷市場規模：按癌症類型分類

• 外分泌性胰臟癌
• 胰臟神經內分泌腫瘤（PNETs）

全球胰臟癌診斷市場規模：依最終用戶分類

• 醫院
• 診斷檢查室
• 癌症研究中心
• 專科診所

全球胰臟癌診斷市場規模：依樣本類型分類

• 血
• 組織切片檢查
• 胰液

全球胰臟癌診斷市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Roche Diagnostics
• Abbott Laboratories
• Siemens Healthineers
• Thermo Fisher Scientific
• Danaher Corporation
• Qiagen
• Bio-Rad Laboratories
• Illumina
• Guardant Health
• Exact Sciences
• Myriad Genetics
• Foundation Medicine
• NeoGenomics Laboratories
• Natera
• Agilent Technologies
• Freenome
• GRAIL
• Genomic Health
• Sysmex Corporation
• Becton Dickinson

結論與建議

Global Pancreatic Cancer Diagnostic Market size was valued at USD 3.40 Billion in 2024 and is poised to grow from USD 3.69 Billion in 2025 to USD 7.09 Billion by 2033, growing at a CAGR of 8.5% during the forecast period (2026-2033).

The pancreatic cancer diagnostic market is significantly driven by the urgent necessity for improved detection methods, prompting considerable investment and innovation. Diverse diagnostic modalities, including imaging techniques, serum and tissue biomarkers, and informatics, collaborate to enhance the accuracy of diagnosis, staging, and treatment strategies. Given the late presentation and low survival rates associated with pancreatic cancer, effective diagnostics can substantially influence patient outcomes and resource distribution. The current focus has transitioned from traditional methods, such as CA19-9 and CT imaging, to advanced options like endoscopic ultrasound, genomics, and liquid biopsies. Furthermore, technological advancements, especially in AI-enhanced imaging and sensitive assays, are fostering market growth, while affordable point-of-care tests are expected to broaden access and stimulate ongoing research initiatives.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pancreatic Cancer Diagnostic market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pancreatic Cancer Diagnostic Market Segments Analysis

Global pancreatic cancer diagnostic market is segmented by product type, technology, application, cancer type, end user, sample type and region. Based on product type, the market is segmented into imaging tests, biomarker tests, molecular diagnostic tests, biopsy devices and reagents & consumables. Based on technology, the market is segmented into PCR-based diagnostics, next-generation sequencing (NGS), immunoassays, imaging technologies and liquid biopsy. Based on application, the market is segmented into early detection, tumor staging, treatment monitoring and recurrence monitoring. Based on cancer type, the market is segmented into exocrine pancreatic cancer and pancreatic neuroendocrine tumors (PNETs). Based on end user, the market is segmented into hospitals, diagnostic laboratories, cancer research centers and specialty clinics. Based on sample type, the market is segmented into blood, tissue biopsy and pancreatic fluid. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Driver of the Global Pancreatic Cancer Diagnostic Market

The global market for pancreatic cancer diagnostics is significantly driven by the rising investments from pharmaceutical and biotech companies in molecular diagnostics. This surge in funding enhances research capabilities, enabling the development of innovative assays and platforms aimed at improving pancreatic cancer detection. With increased resources, companies can discover new biomarkers, conduct essential validation studies, and collaborate with academic and industry partners to expedite the commercialization of research findings. This sustained investment bolsters the necessary infrastructure, cultivates a skilled workforce, and streamlines the introduction of advanced diagnostic tests, thereby expanding access to cutting-edge solutions for pancreatic cancer detection in clinical settings.

Restraints in the Global Pancreatic Cancer Diagnostic Market

The global pancreatic cancer diagnostic market faces notable challenges due to a widespread lack of awareness among primary healthcare providers and inefficient referral patterns that delay specialist consultations. This situation hampers early testing and timely diagnosis for patients with suspected pancreatic cancer, which in turn diminishes the demand for advanced diagnostic tools. Often, patients present with nonspecific symptoms, leading to diagnoses at more advanced stages, thus undermining the perceived value of early detection assays. Furthermore, clinical inertia and a tendency towards conservative referral practices further restrict the adoption of innovative diagnostic methods, resulting in sustained dependence on traditional pathways and stifling overall market growth.

Market Trends of the Global Pancreatic Cancer Diagnostic Market

The global pancreatic cancer diagnostic market is experiencing a significant trend towards the integration of artificial intelligence (AI) technologies. This shift enhances diagnostic accuracy and speed by leveraging AI to analyze imaging and pathology data, allowing healthcare providers to identify patients needing specialty care more efficiently. The collaboration between AI solution vendors and healthcare organizations is leading to the development of validated algorithms and utility studies, which are crucial for improving diagnostic workflows. Additionally, the seamless integration of AI with electronic health records and collaborative platforms is streamlining patient pathways, ultimately elevating the standard of care and clinical decision support in pancreatic cancer management.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape
• Value Chain Analysis
• Case Studies
• Technology Assessment
• Customer & Buying Criteria Analysis
• Pipeline Analysis
• Disease Epidemiology

Global Pancreatic Cancer Diagnostic Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Imaging Tests
• Biomarker Tests
• Molecular Diagnostic Tests
• Biopsy Devices
• Reagents & Consumables

Global Pancreatic Cancer Diagnostic Market Size by Technology & CAGR (2026-2033)

• Market Overview
• PCR-Based Diagnostics
• Next-Generation Sequencing (NGS)
• Immunoassays
• Imaging Technologies
• Liquid Biopsy

Global Pancreatic Cancer Diagnostic Market Size by Application & CAGR (2026-2033)

• Market Overview
• Early Detection
• Tumor Staging
• Treatment Monitoring
• Recurrence Monitoring

Global Pancreatic Cancer Diagnostic Market Size by Cancer Type & CAGR (2026-2033)

• Market Overview
• Exocrine Pancreatic Cancer
• Pancreatic Neuroendocrine Tumors (PNETs)

Global Pancreatic Cancer Diagnostic Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Diagnostic Laboratories
• Cancer Research Centers
• Specialty Clinics

Global Pancreatic Cancer Diagnostic Market Size by Sample Type & CAGR (2026-2033)

• Market Overview
• Blood
• Tissue Biopsy
• Pancreatic Fluid

Global Pancreatic Cancer Diagnostic Market Size & CAGR (2026-2033)

• North America (Product Type, Technology, Application, Cancer Type, End User, Sample Type)
  • US
  • Canada
• Europe (Product Type, Technology, Application, Cancer Type, End User, Sample Type)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Technology, Application, Cancer Type, End User, Sample Type)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Technology, Application, Cancer Type, End User, Sample Type)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Technology, Application, Cancer Type, End User, Sample Type)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Roche Diagnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Qiagen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guardant Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exact Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Foundation Medicine
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NeoGenomics Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Natera
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Freenome
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GRAIL
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genomic Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton Dickinson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations